Earnings Call Summary | YS Biopharma(YS.US) Q3 2024 Earnings Conference
Earnings Call Summary | YS Biopharma(YS.US) Q3 2024 Earnings Conference
The following is a summary of the YS Biopharma Co., Ltd. (YS) Q3 2024 Earnings Call Transcript:
以下是美国生物制药有限公司（YS）2024年第三季度财报电话会议记录摘要：
Financial Performance:
财务业绩：
YS Biopharma reported a total revenue of RMB 438.1 million for the first nine months of fiscal year 2024, a year-over-year decrease by 24.6% due to supply chain disruptions.
Net loss of RMB 260 million was recorded for the same period.
The company projects double-digit growth in product sales for the end of fiscal year 2024 and throughout 2025.
YS Biopharma报告称，2024财年前九个月的总收入为4.381亿元人民币，由于供应链中断，同比下降24.6％。
同期净亏损为人民币2.6亿元。
该公司预计，到2024财年末和整个2025年，产品销售将实现两位数的增长。
Business Progress:
业务进展：
YS Biopharma successfully addressed inventory issues and balanced their strategy to meet market demands.
The company continues to strengthen relationships with CDC customers in China, constituting more than 6% of their network.
Priority placed on pre-clinical and clinical pipeline across all subsidiaries in the US, China, and Singapore.
Successful results from the Phase III trial of their PIKA rabies vaccine show potential for faster production and improved regimen.
The company plans to conduct a Phase 1 study for their Hepatitis B vaccine.
YS Biopharma成功解决了库存问题并平衡了战略以满足市场需求。
该公司继续加强与中国CDC客户的关系，占其网络的6％以上。
优先考虑美国、中国和新加坡所有子公司的临床前和临床产品线。
他们的PIKA狂犬病疫苗三期试验的成功结果表明，有可能加快生产速度和改善治疗方案。
该公司计划对其乙型肝炎疫苗进行1期研究。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由 AI 生成。无法完全保证内容的准确性。欲了解更多详情，请访问投资者关系网站。本文仅供投资者参考，不构成任何投资建议。